Research programme: TNF-alpha antagonists - Gryphon Therapeutics
Alternative Names: D-TNF-α; D-TNF-α therapy research programme - Gryphon Therapeutics; Rheumatoid arthritis therapy research programme - Gryphon TherapeuticsLatest Information Update: 07 Mar 2011
At a glance
- Originator Gryphon Therapeutics
- Class Peptides
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 14 Jun 2004 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)